Market Closed - Nasdaq 21:00:00 22/04/2024 BST 5-day change 1st Jan Change
131.5 USD +0.62% Intraday chart for DexCom, Inc. -2.26% +5.99%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Dexcom Insider Sold Shares Worth $274,242, According to a Recent SEC Filing MT
BTIG Adjusts DexCom's Price Target to $156 From $150 MT
UBS Raises DexCom's Price Target to $163 From $153, Maintains Buy Rating MT
MD Revolution Partners with Dexcom to Integrate Continuous Glucose Monitoring Systems with Its Remote Care Management Platform CI
Citigroup Raises Price Target on DexCom to $161 From $148, Keeps Buy Rating MT
Dexcom Insider Sold Shares Worth $367,472, According to a Recent SEC Filing MT
Dexcom Insider Sold Shares Worth $579,180, According to a Recent SEC Filing MT
Dexcom Insider Sold Shares Worth $10,802,803, According to a Recent SEC Filing MT
Dexcom Insider Sold Shares Worth $2,715,006, According to a Recent SEC Filing MT
Dexcom Insider Sold Shares Worth $1,567,363, According to a Recent SEC Filing MT
Dexcom Insider Sold Shares Worth $1,182,680, According to a Recent SEC Filing MT
DexCom Initiated at Outperform by RBC, Price Target Set at $165 on View for Revenue Upside Amid Rapidly Expanding Market MT
DexCom is still in the running Our Logo
Sector Update: Health Care Stocks Higher Late Afternoon MT
Sector Update: Health Care Stocks Advance Wednesday Afternoon MT
DexCom Shares Rise After Prescription-Free Glucose Biosensor Wins FDA Clearance MT
US FDA clears use of first over-the-counter continuous glucose monitor RE
DexCom Says Prescription-Free Glucose Biosensor Wins FDA Clearance MT
US FDA clears use of first over-the-counter continuous glucose monitor RE
DexCom, Inc. Announces the FDA Clears Stelo by Dexcom ? the First Glucose Biosensor CI
DexCom Says Use of Automated Insulin Delivery System Reduces Hypoglycemia in Diabetes Patients MT
Transcript : DexCom, Inc. Presents at 45th Annual Raymond James Institutional Investors Conference 2024, Mar-05-2024 08:40 AM
DexCom, Inc. Showcases Leadership in AID and Power of Dexcom CGM in Type 2 Diabetes with New Data at ATTD CI
ANALYST RECOMMENDATIONS : Airbnb, Conagra Brands, Berkshire Hathaway, Meta Platforms, Unilever.... Our Logo
UBS Adjusts DexCom Price Target to $153 From $149, Maintains Buy Rating MT
Chart DexCom, Inc.
More charts
DexCom, Inc. specializes in the design, manufacture and marketing of continuous glucose monitoring (CGM) systems for people with diabetes and healthcare providers. The company provides an implantable device for continuous measurement of blood glucose levels and an external transmitter to which the sensor transmits glucose levels at specified intervals. The United States accounts for 72.5% of net sales.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
131.5 USD
Average target price
149.3 USD
Spread / Average Target
+13.51%
Consensus
  1. Stock Market
  2. Equities
  3. DXCM Stock
  4. News DexCom, Inc.
  5. TD Cowen Adjusts DexCom Price Target to $160 From $110, Maintains Outperform Rating